Showing results (201-210 of 277) with videos related to

Sort By:
Pageof 28
Journal of Alzheimer'S Disease : JAD|June 6, 2018
Role of Amyloid-β and Tau Proteins in Alzheimer's Disease: Confuting the Amyloid CascadeWalter Gulisano, Daniele Maugeri, Marian A Baltrons, et al.
Contemporary Clinical Trials|December 10, 2013
Donepezil treatment of older adults with cognitive impairment and depression (DOTCODE study): clinical rationale and designGregory H Pelton, Howard Andrews, Steven P Roose, et al.
International Forum of Allergy & Rhinology|March 31, 2026
Recovery of Parosmia Preferentially Influences Longitudinal Improvement of Quality of Life in C19ODTiana M Saak, Jeremy P Tervo, Brandon J Vilarello, et al.
Journal of Alzheimer'S Disease : JAD|March 1, 2021
Olfactory Impairment Is Related to Tau Pathology and Neuroinflammation in Alzheimer's DiseaseJulia Klein, Xinyu Yan, Aubrey Johnson, et al.
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry|November 17, 2004
Altered PET functional brain responses in cognitively intact elderly persons at risk for Alzheimer disease (carriers of the epsilon4 allele)Nikolaos Scarmeas, Christian Habeck, Karen E Anderson, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|November 18, 2005
PET network abnormalities and cognitive decline in patients with mild cognitive impairmentDavangere P Devanand, Christian G Habeck, Matthias H Tabert, et al.
Journal of Alzheimer'S Disease : JAD|October 31, 2017
Change in Odor Identification Impairment is Associated with Improvement with Cholinesterase Inhibitor Treatment in Mild Cognitive ImpairmentD P Devanand, Cody Lentz, Richard E Chunga, et al.
Archives of General Psychiatry|March 1, 1997
The course of psychopathologic features in mild to moderate Alzheimer diseaseD P Devanand, D M Jacobs, M X Tang, et al.
International Journal of Clinical Trials|August 25, 2025
Crossword puzzle training and neuroplasticity in mild cognitive impairment (COGIT-2): 78-week, multi-site, randomized controlled trial with cognitive, functional, imaging and biomarker outcomesLaura A Wang, Terry E Goldberg, Philip D Harvey, et al.
Plos One|December 14, 2022
Chemosensory deficits are best predictor of serologic response among individuals infected with SARS-CoV-2Jonathan B Overdevest, Alexandria L Irace, Valeria Mazzanti, et al.
Pageof 28